

# Risk estimation for hepatocellular carcinoma in chronic development and validation of a predictive score

Lancet Oncology, The

12, 568-574

DOI: [10.1016/s1470-2045\(11\)70077-8](https://doi.org/10.1016/s1470-2045(11)70077-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Risk score for development of HCC: ready for use in practice?. <i>Lancet Oncology</i> , The, 2011, 12, 517-518.	5.1	5
2	Risk score for development of HCC: ready for use in practice? â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 518-519.	5.1	0
3	â€¦ and a two-edged sword in their hands. <i>Lancet Oncology</i> , The, 2011, 12, 519-520.	5.1	0
4	FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2512-2517.	1.1	37
5	Early Diagnosis of Hepatocellular Carcinoma by Multiple microRNAs: Validity, Efficacy, and Cost-Effectiveness. <i>Journal of Clinical Oncology</i> , 2011, 29, 4745-4747.	0.8	23
6	Screening for Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2011, 2011, 1-4.	0.4	8
8	Diagnosis and personalized management of hepatitis B including significance of genotypes. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 570-577.	1.3	15
9	Epidemiology and Surveillance of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 2-14.	4.2	144
10	mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma. <i>Current Cancer Drug Targets</i> , 2012, 12, 1045-1061.	0.8	22
11	Editorial [Hot Topic: Recent Advances in the Prevention and Therapy of Hepatocellular Carcinoma]. <i>Current Cancer Drug Targets</i> , 2012, 12, 1043-1044.	0.8	2
12	HBV-related hepatocellular carcinoma: the role of integration, viral proteins and miRNA. <i>Future Virology</i> , 2012, 7, 1237-1249.	0.9	1
13	Noninvasive assessment of liver fibrosis via spleen stiffness measurement using acoustic radiation force impulse sonoelastography in patients with chronic hepatitis B or C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 654-663.	1.0	27
14	Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. <i>Lancet Oncology</i> , The, 2012, 13, 633-641.	5.1	274
15	Natural history of chronic hepatitis <scp>B</scp>: what exactly has <scp>REVEAL</scp> Revealed?. <i>Liver International</i> , 2012, 32, 1333-1341.	1.9	99
16	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. <i>Journal of Hepatology</i> , 2012, 56, 1089-1096.	1.8	61
17	Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. <i>BMC Gastroenterology</i> , 2012, 12, 105.	0.8	50
18	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	0.6	469
19	Identifying Hepatitis B Carriers at Low Risk for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2012, 142, 1057-1060.	0.6	22

#	ARTICLE	IF	CITATIONS
20	Diverse roles of hepatitis B virus in liver cancer. <i>Current Opinion in Virology</i> , 2012, 2, 467-473.	2.6	46
21	Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada. <i>Value in Health</i> , 2012, 15, 894-906.	0.1	17
22	Fifteen-Year Population Attributable Fractions and Causal Pies of Risk Factors for Newly Developed Hepatocellular Carcinomas in 11,801 Men in Taiwan. <i>PLoS ONE</i> , 2012, 7, e34779.	1.1	16
23	Management of Chronic Hepatitis B: Canadian Association for the Study of the Liver Consensus Guidelines. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 917-938.	1.8	60
24	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-293.	0.6	22
25	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	1.9	874
26	Risk assessment for hepatocellular carcinoma in chronic hepatitis B: scores and surveillance. <i>International Journal of Clinical Practice</i> , 2012, 66, 7-10.	0.8	7
27	Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen. <i>Tzu Chi Medical Journal</i> , 2013, 25, 75-81.	0.4	3
28	Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. <i>British Journal of Cancer</i> , 2013, 109, 2481-2488.	2.9	63
29	New Insights in the Diagnosis, Pathogenesis and Treatment of Hepatitis B- and C-related Hepatocellular Carcinoma. <i>Current Hepatitis Reports</i> , 2013, 12, 297-304.	0.3	2
30	Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. <i>Journal of Gastroenterology</i> , 2013, 48, 13-21.	2.3	106
31	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-“Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	1.9	45
32	A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. <i>Journal of Hepatology</i> , 2013, 58, 853-860.	1.8	80
33	Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma. <i>Medical Oncology</i> , 2013, 30, 360.	1.2	10
34	Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 243-251.	1.9	14
35	Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment. <i>Gastroenterology</i> , 2013, 144, 933-944.	0.6	155
36	Risk stratification for hepatitis B virus related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 10-17.	1.4	82
37	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. <i>Hepatology</i> , 2013, 58, 98-107.	3.6	596

#	ARTICLE	IF	CITATIONS
38	Risk for Tuberculosis in Child Contacts. Development and Validation of a Predictive Score. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 203-213.	2.5	24
39	Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles. <i>Hepatology</i> , 2013, 58, 546-554.	3.6	271
41	Predicting clinical outcome in a patient with chronic hepatitis B virus infection. <i>Clinical Liver Disease</i> , 2013, 2, 5-7.	1.0	0
42	Commentary: prognostication of chronic hepatitis B –are Fibrotest and Fibroscan the final answers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1113-1113.	1.9	1
43	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. <i>OncoTargets and Therapy</i> , 2013, 6, 1463.	1.0	22
44	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 6515.	1.4	38
45	Predictability of Liver-Related Seromarkers for the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2013, 8, e61448.	1.1	34
46	Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. <i>African Health Sciences</i> , 2013, 13, 703-9.	0.3	31
47	Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 21.	1.8	2
48	Current developments in nucleoside/nucleotide analogues for hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 607-622.	1.4	36
49	Hepatocellular Carcinoma Screening and Diagnosis. <i>Seminars in Liver Disease</i> , 2014, 34, 389-397.	1.8	15
50	Managing hepatitis B to prevent liver cancer: recent advances. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 409-415.	1.4	3
51	Impact of HBV therapy on the incidence of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 139-145.	1.9	31
52	Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model. <i>Cancer</i> , 2014, 120, 3485-3493.	2.0	125
53	Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1920-1927.	1.3	37
54	Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels. <i>JAMA Surgery</i> , 2014, 149, 519.	2.2	43
55	The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1262-1269.	1.9	53
56	A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 1359-1368.	2.3	95

#	ARTICLE	IF	CITATIONS
57	Hepatitis B virus-induced hepatocellular carcinoma. <i>Cancer Letters</i> , 2014, 345, 216-222.	3.2	116
58	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014, 60, 339-345.	1.8	227
59	Epidemiology of Virus Infection and Human Cancer. <i>Recent Results in Cancer Research</i> , 2014, 193, 11-32.	1.8	72
60	Screening for liver cancer: Another piece of the puzzle?. <i>Hepatology</i> , 2014, 59, 1673-1675.	3.6	2
61	Combinations of eight key mutations in the X <sub>pre</sub> C region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2014, 21, 171-177.	1.0	43
62	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1173-1180.	2.8	110
64	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014, 59, 986-995.	3.6	114
65	Surveillance for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 783-793.	1.0	48
66	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249.	0.2	120
67	Role of antiviral treatment for HCC prevention. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 771-781.	1.0	31
68	Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study. <i>Gastroenterology</i> , 2014, 147, 143-151.e5.	0.6	267
69	Averting Hepatocellular Carcinoma in Chronic Hepatitis B With Antiviral Therapy: Tipping the Balance or Not Yet?. <i>Gastroenterology</i> , 2014, 147, 24-26.	0.6	2
70	Personalized management of hepatocellular carcinoma based on molecular information: Future prospects. <i>Clinical Liver Disease</i> , 2015, 5, 132-135.	1.0	4
71	Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk-scoring schemes. <i>International Journal of Cancer</i> , 2015, 136, 340-349.	2.3	23
73	Hepatoma in hepatitis B: Infectious disease or liver disease?. <i>Hepatology</i> , 2015, 62, 1662-1663.	3.6	0
74	A new risk estimation scale of HCC development, named JAB-HCC score (Japanese risk estimations of) Tj ETQq1 1 0,784314 rgBT /Over	0.0	0
75	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , 2015, 121, 3631-3638.	2.0	173
76	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766.	3.6	97

#	ARTICLE	IF	CITATIONS
77	Surveillance for hepatocellular carcinoma in chronic hepatitis B virus infection: for whom. <i>Hepatic Oncology</i> , 2015, 2, 225-229.	4.2	1
78	Risk scores for hepatocellular carcinoma in chronic hepatitis B. <i>Hepatology</i> , 2015, 61, 1784-1786.	3.6	4
79	HBeAg-negative chronic hepatitis patients should be monitored more strictly: A cross-sectional retrospective study on antiviral treatment-naïve patients. <i>Journal of Medical Virology</i> , 2015, 87, 1682-1688.	2.5	4
80	Hepatocellular Carcinoma: Consensus, Controversies and Future Directions: A Report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 178-184.	0.8	37
81	New challenges in clinical research on hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 485-93.	0.1	12
82	Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. <i>World Journal of Hepatology</i> , 2015, 7, 1064.	0.8	46
83	Molecular prognostic prediction in liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 10262.	1.4	12
84	Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. <i>Journal of Hepatology</i> , 2015, 63, 722-732.	1.8	97
85	Author's response: Hepatitis B virus seromarkers clearance and risk of hepatocellular carcinoma: serious risks of misinterpretation. <i>Gut</i> , 2015, 64, 186.2-187.	6.1	0
86	Hepatocellular carcinoma risk scores: ready to use in 2015?. <i>Hepatic Oncology</i> , 2015, 2, 1-4.	4.2	4
87	Management of Chronic Hepatitis B: An Overview of Practice Guidelines for Primary Care Providers. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 822-837.	0.8	20
88	Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 439-451.	1.0	5
89	Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. <i>Journal of Infectious Diseases</i> , 2015, 211, 1566-1573.	1.9	18
90	Hepatocellular Carcinoma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021444-a021444.	2.9	86
91	Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	6.1	234
92	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	1.8	398
93	What can we learn from hepatitis B virus clinical cohorts?. <i>Liver International</i> , 2015, 35, 91-99.	1.9	12
94	Comorbidity predicts poor prognosis in nasopharyngeal carcinoma: Development and validation of a predictive score model. <i>Radiotherapy and Oncology</i> , 2015, 114, 249-256.	0.3	21

#	ARTICLE	IF	CITATIONS
95	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastographyâ€defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859.	3.6	121
96	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	1.8	138
97	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015, 64, 1289-1295.	6.1	178
98	Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. <i>Clinical Microbiology and Infection</i> , 2015, 21, 969-974.	2.8	29
99	Improving clinical outcomes of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 141-154.	1.4	24
100	Novel score for prediction of malignant bile duct obstruction based on biochemical and clinical markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 877-887.	1.9	7
101	Hepatitis B vaccination and prevention of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 907-917.	1.0	80
102	Perspectives and control of hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 901-909.	0.8	63
103	Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study. <i>Cancer Prevention Research</i> , 2015, 8, 978-988.	0.7	21
104	Outcomes of Patients With Chronic Hepatitis B Who Do Not Meet Criteria for Antiviral Treatment at Presentation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 193-201.e1.	2.4	24
105	Predicting suicide in older adults â€ a community-based cohort study in Taipei City, Taiwan. <i>Journal of Affective Disorders</i> , 2015, 172, 165-170.	2.0	25
106	Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Mori: results from a 28-year follow-up study. <i>Gut</i> , 2015, 64, 966-972.	6.1	28
107	Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2016, 22, 8314.	1.4	52
108	How to Develop, Validate, and Compare Clinical Prediction Models Involving Radiological Parameters: Study Design and Statistical Methods. <i>Korean Journal of Radiology</i> , 2016, 17, 339.	1.5	127
109	The significance of low levels of LINC RP1130-1 expression in human hepatocellular carcinoma. <i>BioScience Trends</i> , 2016, 10, 378-385.	1.1	10
110	Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. <i>World Journal of Gastroenterology</i> , 2016, 22, 6565.	1.4	3
111	Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anticancer therapy. <i>International Journal of Cancer</i> , 2016, 138, 1601-1608.	2.3	26
112	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42

#	ARTICLE	IF	CITATIONS
113	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 720-731.	3.6	13
114	Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1971-1977.	1.4	26
115	Tratamiento personalizado del carcinoma hepatocelular basado en información molecular: perspectivas futuras. <i>Clinical Liver Disease</i> , 2016, 8, S43-S48.	1.0	0
116	Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score. <i>GE Portuguese Journal of Gastroenterology</i> , 2016, 23, 233-242.	0.3	4
117	Nontumor Prognostic Factors in Hepatocellular Carcinoma. , 2016, , 139-147.		2
118	Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1291-1302.	1.1	4
119	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.1	2
120	Surveillance for Hepatocellular Carcinoma. , 2016, , 339-354.		1
121	Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 846-855.	1.9	47
122	Management of HBV and HBV/HDV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 86-94.	0.5	16
123	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	3.6	75
124	Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 110-115.	0.5	9
125	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	18.1	1,863
126	Surveillance for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 1001-1010.	1.0	25
127	Prevention of Hepatocellular Carcinoma. <i>Gastrointestinal Tumors</i> , 2016, 3, 37-43.	0.3	17
128	Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. <i>Medicine (United States)</i> , 2016, 95, e4433.	0.4	35
129	A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. <i>Medicine (United States)</i> , 2016, 95, e4832.	0.4	7
130	Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. <i>Cancer Prevention Research</i> , 2016, 9, 758-765.	0.7	41



#	ARTICLE	IF	CITATIONS
131	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 1297-1304.	0.2	39
132	Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. <i>BMC Gastroenterology</i> , 2016, 16, 13.	0.8	16
133	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	6.1	39
134	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	0.6	1,365
135	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	2.4	24
136	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , 2016, 34, 83-90.	0.8	131
137	Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016, 213, 966-974.	1.9	60
138	Personalized therapy for hepatocellular carcinoma: Where are we now?. <i>Cancer Treatment Reviews</i> , 2016, 45, 77-86.	3.4	51
139	Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Oncology</i> , 2016, 90, 199-208.	0.9	9
141	Liver cancer screening in high-risk populations. <i>Hepatic Oncology</i> , 2016, 3, 13-18.	4.2	1
142	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	1.8	358
143	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	1.9	1,908
144	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	1.9	64
145	The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. <i>Gut</i> , 2016, 65, 1347-1358.	6.1	40
146	Treatment of chronic hepatitis B infection in 2017. <i>Liver International</i> , 2017, 37, 59-66.	1.9	22
147	Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. <i>Clinical and Translational Oncology</i> , 2017, 19, 844-852.	1.2	33
148	Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (<sc>NUC</sc>s). <i>Liver International</i> , 2017, 37, 45-51.	1.9	65
149	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , 2017, 11, 268-276.	1.9	23

#	ARTICLE	IF	CITATIONS
150	Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. <i>BMC Infectious Diseases</i> , 2017, 17, 9.	1.3	1
151	Validation of PAGE model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	1.9	37
152	Mechanism and prediction of HCC development in HBV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 291-298.	1.0	22
153	Toll like receptor 4 and hepatocellular carcinoma; A systematic review. <i>Life Sciences</i> , 2017, 179, 80-87.	2.0	48
154	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	3.6	239
155	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
156	Surveillance of the Patients with High Risk of Hepatocellular Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 246-249.	0.6	1
157	Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE score. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1023-1031.	1.0	24
158	HBV markers for HCC prediction: Three heads are better than two?. <i>Journal of Hepatology</i> , 2017, 67, 203-204.	1.8	6
159	A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients. <i>Scientific Reports</i> , 2017, 7, 523.	1.6	32
160	Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?. <i>Current Hepatology Reports</i> , 2017, 16, 64-71.	0.4	17
161	Building a genetic risk model for bipolar disorder from genome-wide association data with random forest algorithm. <i>Scientific Reports</i> , 2017, 7, 39943.	1.6	27
162	Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 999-1008.	1.4	19
163	Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2017, 7, 14352.	1.6	24
164	Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 12-20.	1.0	21
165	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.2	44
166	Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers. <i>Scientific Reports</i> , 2017, 7, 11169.	1.6	14
167	How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. <i>Journal of Hepatology</i> , 2017, 67, 1281-1297.	1.8	132

#	ARTICLE	IF	CITATIONS
168	Response to Dr Giannini et al.. American Journal of Gastroenterology, 2017, 112, 1340-1341.	0.2	0
169	Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. Carcinogenesis, 2017, 38, 1021-1028.	1.3	37
170	Hepatitis B cure: From discovery to regulatory approval. Journal of Hepatology, 2017, 67, 847-861.	1.8	189
171	Hepatitis B cure: From discovery to regulatory approval. Hepatology, 2017, 66, 1296-1313.	3.6	235
172	Clonorchis sinensis infection and co-infection with the hepatitis B virus are important factors associated with cholangiocarcinoma and hepatocellular carcinoma. Parasitology Research, 2017, 116, 2645-2649.	0.6	10
173	The US Food and Drug Administration's tentative approval process and the global fight against HIV. Journal of the International AIDS Society, 2017, 20, e25019.	1.2	5
174	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology, 2017, 67, 902-908.	1.8	112
176	Prognosis of patients with chronic hepatitis B in France (2008â€“2013): A nationwide, observational and hospital-based study. Journal of Hepatology, 2017, 66, 514-520.	1.8	28
177	Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver. American Journal of Gastroenterology, 2017, 112, 460-470.	0.2	23
178	Gene Polymorphisms of <i>TLR2</i> and <i>TLR3</i> in HBV Clearance and HBV-Related Hepatocellular Carcinoma in a Chinese Male Population. International Journal of Biological Markers, 2017, 32, 195-201.	0.7	13
179	Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. Journal of Infectious Diseases, 2017, 216, S757-S764.	1.9	9
180	HCC Risk Scores: Useful or Not?. Seminars in Liver Disease, 2017, 37, 287-295.	1.8	12
181	Hepatitis B virus infection and alcohol consumption. World Journal of Gastroenterology, 2017, 23, 2651.	1.4	49
182	Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. Oncotarget, 2017, 8, 113213-113224.	0.8	24
183	HbA1c-Based Score Model for Predicting Death Risk in Patients with Hepatocellular Carcinoma and Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2017, 2017, 1-7.	1.0	4
184	Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. Journal of Cancer, 2017, 8, 152-161.	1.2	26
185	Screening for hepatocellular carcinoma: patient selection and perspectives. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 71-79.	1.8	27
186	Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. Cancer Epidemiology, 2018, 53, 195-199.	0.8	5

#	ARTICLE	IF	CITATIONS
187	Hepatocellular carcinoma: Present and future. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 390-397.	0.1	14
188	Multi-regional sequencing reveals intratumor heterogeneity and positive selection of somatic mtDNA mutations in hepatocellular carcinoma and colorectal cancer. <i>International Journal of Cancer</i> , 2018, 143, 1143-1152.	2.3	21
189	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
190	Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. <i>Gut</i> , 2018, 67, gutjnl-2017-315407.	6.1	27
191	INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 58-80.	0.4	17
192	Hepatitis B Virus and Liver Disease. , 2018, , .		1
193	Review article: the prevention of hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 5-14.	1.9	41
194	Exploring the use of telephone helpline pertaining to older adult suicide prevention: A Hong Kong experience. <i>Journal of Affective Disorders</i> , 2018, 236, 75-79.	2.0	31
195	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 278-285.	1.8	120
196	High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. <i>Gut</i> , 2018, 67, 945-952.	6.1	176
197	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403.	0.8	92
198	Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1131-1137.	1.4	9
199	Review article: hepatitis B core-related antigen (<sc>HB</sc>crAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 43-54.	1.9	161
200	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. <i>Journal of Hepatology</i> , 2018, 68, 526-549.	1.8	506
201	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686.	1.9	22
202	Carcinoma hepatocelular: presente y futuro. <i>Medicina Clínica</i> , 2018, 150, 390-397.	0.3	35
203	HBV infection and HCC: the "dangerous liaisons"™. <i>Gut</i> , 2018, 67, 787-788.	6.1	20
204	Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 108-113.	4.5	46

#	ARTICLE	IF	CITATIONS
205	Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. Canadian Liver Journal, 2018, 1, 156-217.	0.3	56
206	Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. Current Hepatology Reports, 2018, 17, 502-510.	0.4	1
207	Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1153-1166.	1.4	8
208	Apoptosis and necroptosis in the liver: a matter of life and death. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 738-752.	8.2	364
209	Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study. Seminars in Oncology, 2018, 45, 264-274.	0.8	11
210	Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opinion on Biological Therapy, 2018, 18, 1085-1094.	1.4	24
211	Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B—First study in children. Indian Journal of Gastroenterology, 2018, 37, 326-334.	0.7	9
212	Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea. Hepatology Research, 2018, 48, 862-871.	1.8	23
213	Identification and medical utilization of incident cases of alcohol dependence: A population-based case-control study. Drug and Alcohol Dependence, 2018, 188, 216-223.	1.6	3
214	Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. Journal of Hepatology, 2018, 69, 776-784.	1.8	55
215	Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. Journal of Hepatology, 2018, 69, 1066-1073.	1.8	160
216	Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. Scientific Reports, 2018, 8, 12787.	1.6	17
217	Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. Journal of Hepatology, 2018, 69, 1088-1098.	1.8	119
218	Hepatitis B virus infection. Nature Reviews Disease Primers, 2018, 4, 18035.	18.1	490
221	Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score—Matched Study. Journal of Infectious Diseases, 2019, 219, 10-18.	1.9	72
222	&lt;p&gt;Status of, and strategies for improving, adherence to HCC screening and surveillance&lt;/p&gt;. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 131-141.	1.8	18
223	KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology, 2019, 25, 93-159.	4.5	171
224	Independent risk factors for disease recurrence after surgery in patients with hepatitis B virus-related hepatocellular carcinoma ≥3 cm in diameter. Gastroenterology Report, 2019, 7, 250-257.	0.6	7

#	ARTICLE	IF	CITATIONS
225	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1473-1480.	1.0	22
226	Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 471-471.	1.9	0
227	Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. <i>Molecular and Translational Medicine</i> , 2019, , 3-25.	0.4	6
229	Current perspectives into the evaluation and management of hepatitis B: a review. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 361-369.	0.7	12
230	Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. <i>Nature Communications</i> , 2019, 10, 3192.	5.8	28
231	Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B. <i>Epidemiology and Infection</i> , 2019, 147, e193.	1.0	5
232	Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study. <i>Hepatology Research</i> , 2019, 49, 1263-1274.	1.8	18
233	Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials. <i>Clinics in Liver Disease</i> , 2019, 23, 401-416.	1.0	41
234	CNN-Based Macropixel-Level Up-Sampling for Plenoptic Image Coding. <i>IEEE Access</i> , 2019, 7, 80020-80026.	2.6	1
235	Efficient scheduling for multi-stage coflows. <i>CCF Transactions on Networking</i> , 2019, 2, 83-97.	1.0	1
236	How to improve HCC surveillance outcomes. <i>JHEP Reports</i> , 2019, 1, 460-467.	2.6	8
237	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	1.9	54
239	A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. , 2019, 7, 233.		34
240	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	0.6	83
241	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 23-30.	1.8	16
242	Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study. <i>World Journal of Surgical Oncology</i> , 2019, 17, 75.	0.8	11
243	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1262-1270.	0.9	2
244	Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. <i>Gastroenterology</i> , 2019, 157, 54-64.	0.6	297

#	ARTICLE	IF	CITATIONS
245	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	1.9	29
246	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 856-865.	1.0	17
247	Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. <i>Hepatology International</i> , 2019, 13, 260-269.	1.9	18
248	Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1450-1462.	13.9	2,966
249	Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2039-2048.	1.1	7
251	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1817-1823.	1.4	12
252	Prediction of fetal loss in Chinese pregnant patients with systemic lupus erythematosus: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e023849.	0.8	17
253	Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. , 2019, 7, 298.		40
254	Estimating the Risk of Pneumonia in Patients With Schizophrenia Newly Receiving Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 297-304.	0.7	10
255	Prediction model for hepatocellular carcinoma risk in treatment-naïve chronic hepatitis B patients receiving entecavir/tenofovir. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 865-872.	0.8	44
256	Epidemiology and Management of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 477-491.e1.	0.6	1,133
257	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	0.8	64
258	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. <i>Gastroenterology</i> , 2019, 156, 400-417.	0.6	35
259	Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. <i>Journal of Viral Hepatitis</i> , 2019, 26, 576-585.	1.0	19
260	Non-virological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of ANRS CO-12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	1.0	16
261	A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China. <i>Gut</i> , 2019, 68, 948-949.	6.1	21
262	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	0.6	156
263	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	1.9	58

#	ARTICLE	IF	CITATIONS
265	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 693-699.e1.	2.4	24
266	Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2130-2139.	1.1	7
267	Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. <i>Liver International</i> , 2020, 40, 484-495.	1.9	42
268	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	1.8	49
269	Role of Biomarkers in Guiding Cure of Viral Hepatitis B. <i>Seminars in Liver Disease</i> , 2020, 40, 049-060.	1.8	13
270	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 397-406.	1.0	16
271	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
272	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
273	Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1520-1530.	2.4	23
274	Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma. <i>Immunogenetics</i> , 2020, 72, 455-465.	1.2	17
275	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. <i>Journal of Clinical Medicine</i> , 2020, 9, 3843.	1.0	10
276	Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. <i>International Journal of Epidemiology</i> , 2020, 49, 1562-1571.	0.9	14
277	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. <i>Scientific Reports</i> , 2020, 10, 13021.	1.6	8
278	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550.	1.9	36
279	Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?. <i>Journal of Gastroenterology</i> , 2020, 55, 1023-1036.	2.3	10
280	Novel Calculators for Risk Stratification in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 789-794.	1.1	1
281	Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 575-576.	1.9	1
282	Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 576-577.	1.9	1



#	ARTICLE	IF	CITATIONS
283	Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3456-3462.	1.1	10
284	Abundance of Noncircular Intrahepatic Hepatitis B Virus DNA May Reflect Frequent Integration Into Human DNA in Chronically Infected Patients. <i>Journal of Infectious Diseases</i> , 2022, 225, 1982-1990.	1.9	11
285	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	1.0	6
286	Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060.	1.0	7
287	On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1177.	1.7	11
288	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.1	3
289	Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: <scp>REVEAL</scp> and <scp>HCV</scp> studies. <i>International Journal of Cancer</i> , 2020, 147, 2743-2753.	2.3	28
290	Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. <i>Gut</i> , 2020, 69, 1907-1912.	6.1	14
291	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020, 55, 899-908.	2.3	18
292	Assessment of HCC Risk in Patients with Chronic HBV (REACH, PAGE-B, and Beyond). <i>Current Hepatology Reports</i> , 2020, 19, 285-292.	0.4	2
293	Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Endometrial Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 456.	1.1	7
294	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	1.8	43
295	HBV DNA and HBsAg: Early Prediction of Response to Peginterferon $\alpha$ -2a in HBeAg-Negative Chronic Hepatitis B. <i>International Journal of Medical Sciences</i> , 2020, 17, 383-389.	1.1	7
296	Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. <i>Hepatology</i> , 2020, 72, 2197-2205.	3.6	18
297	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2020, 19, 546-569.	0.6	11
298	External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 882-888.	0.8	7
299	Hepatitis B: Who to treat? A critical review of international guidelines. <i>Liver International</i> , 2020, 40, 5-14.	1.9	25
300	Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1595-1601.	1.4	18

#	ARTICLE	IF	CITATIONS
301	Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1684-1693.	1.4	17
302	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. <i>Liver International</i> , 2020, 40, 1736-1743.	1.9	23
303	Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1169-1179.	1.9	50
304	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	1.1	2
305	Epidemiology of Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 4-13.	3.6	1,007
306	Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101436.	0.7	5
307	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	1.0	8
308	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416.	1.8	5
309	Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 493-507.	1.0	42
310	Epidemiology and Natural History of Hepatitis B Virus Infection: Time-Dependent Driving Factors of Chronic Hepatitis B Progression. , 2021, , 143-167.		0
311	Distinct Impacts of Pre-Operative Antiviral Treatment on Post-Operative Outcomes of HBV-related Hepatocellular Carcinoma: A Landmark Analysis. <i>Journal of Cancer</i> , 2021, 12, 170-180.	1.2	3
312	Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. , 2021, 7, .		7
313	A prediction model of delayed graft function in deceased donor for renal transplant: a multi-center study from China. <i>Renal Failure</i> , 2021, 43, 520-529.	0.8	3
314	One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , 2021, 15, 105-113.	1.9	6
315	Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 826-836.	1.0	7
316	Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. <i>Journal of Viral Hepatitis</i> , 2021, 28, 787-794.	1.0	7
317	Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era. <i>GastroHep</i> , 2021, 3, 80-87.	0.3	4
318	Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people. <i>International Journal of Cancer</i> , 2021, 148, 2924-2934.	2.3	6

#	ARTICLE	IF	CITATIONS
319	Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.3	7
320	Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2499-2513.	2.4	26
321	Prediction of Hepatocellular Carcinoma by On-Therapy Response of Noninvasive Fibrosis Markers in Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2021, 116, 1657-1666.	0.2	4
322	A new risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199766.	0.4	1
323	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304.	4.5	19
324	Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1034-1041.	1.0	4
325	Identification of Resectable N2 in NSCLC: A Single Center Experience and Review of the SEER Database. <i>Frontiers in Oncology</i> , 2021, 11, 647546.	1.3	5
326	HLA Zygosity Increases Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	7
327	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	1.6	17
328	In search of an evidence base for HCC surveillance: Purity or pragmatism?. <i>Journal of Hepatology</i> , 2021, 74, 1025-1027.	1.8	1
329	Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model. <i>BMC Cancer</i> , 2021, 21, 639.	1.1	4
331	Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	6
332	Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients. <i>World Journal of Clinical Cases</i> , 2021, 9, 3238-3251.	0.3	4
333	The Use of IgY (Immunoglobulin Yolk) in Cancer Prevention Seen in Liver and Stomach Cancers. , 2021, , .		0
334	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
335	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	1.8	2
336	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	2.4	4
337	Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. <i>Seminars in Liver Disease</i> , 2021, 41, 285-297.	1.8	7

#	ARTICLE	IF	CITATIONS
338	Prediction of the risk of developing hepatocellular carcinoma in health screening examinees: a Korean cohort study. <i>BMC Cancer</i> , 2021, 21, 755.	1.1	7
339	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	2.6	5
340	Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. <i>Viruses</i> , 2021, 13, 1318.	1.5	2
341	Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 448-450.	4.5	0
342	Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study. <i>BMJ Open</i> , 2021, 11, e046115.	0.8	5
343	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101766.	0.7	0
344	Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. <i>Viruses</i> , 2021, 13, 1333.	1.5	2
345	External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1373-1380.	1.0	5
346	Comparison of Interferon- $\alpha$ -based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101758.	0.7	5
347	External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy. <i>Frontiers in Medicine</i> , 2021, 8, 677920.	1.2	11
348	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
349	Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-10.	0.8	9
350	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1526-1538.	1.0	6
351	Surveillance for hepatocellular carcinoma in people of African ancestry with HIV and Hepatitis B. <i>International Journal of STD and AIDS</i> , 2021, , 095646242110428.	0.5	3
352	New Thresholds for AFP and Des- $\gamma$ -Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6149-6165.	0.8	1
353	Hepatitis B Virus (HBV) - Induced Hepatocarcinogenesis, a Founding Framework of Cancer Evolution & Development (Cancer Evo-Dev). , 0, , .		0
354	Hepatocellular Carcinoma: Diagnosis and Surveillance. , 0, , .		1
355	Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 686962.	1.3	18

#	ARTICLE	IF	CITATIONS
356	Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?. <i>World Journal of Gastroenterology</i> , 2021, 27, 5536-5554.	1.4	6
357	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	2.4	9
358	Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. <i>Journal of Hepatology</i> , 2022, 76, 294-301.	1.8	20
359	Long-term oncologic outcomes of liver resection for hepatocellular carcinoma in adolescents and young adults: A multicenter study from a hepatitis B virus-endemic area. <i>American Journal of Surgery</i> , 2021, 222, 751-758.	0.9	4
360	External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population. <i>JHEP Reports</i> , 2021, 3, 100343.	2.6	2
361	Controversies in Treating Chronic Hepatitis B virus. <i>Clinics in Liver Disease</i> , 2021, 25, 763-784.	1.0	1
362	Controversies in the Management of Hepatitis B. <i>Clinics in Liver Disease</i> , 2021, 25, 785-803.	1.0	4
363	Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. <i>Clinics in Liver Disease</i> , 2021, 25, 725-740.	1.0	5
364	Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 919-927.	1.9	7
365	Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 262-267.	0.8	5
366	Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. <i>Hepatology International</i> , 2021, 15, 82-92.	1.9	3
367	The Role of Elastography in HBV: Assessing Liver Fibrosis. , 2021, , 43-59.		0
368	Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 479.	1.8	15
369	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	1.3	9
370	Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection. , 2021, , 205-230.		0
371	Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. <i>PLoS ONE</i> , 2021, 16, e0244939.	1.1	22
374	Epidemiology of Virus Infection and Human Cancer. <i>Recent Results in Cancer Research</i> , 2021, 217, 13-45.	1.8	19
375	Natural History of HBV Infection in the Community. <i>Molecular and Translational Medicine</i> , 2016, , 249-276.	0.4	2

#	ARTICLE	IF	CITATIONS
376	Epidemiology, Diagnosis, and Natural History of Hepatitis B. , 2018, , 474-484.e4.		5
377	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2021, 33, 885-893.	0.8	4
378	Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World Journal of Clinical Cases, 2019, 7, 2269-22286.	0.3	21
379	Surveillance of Hepatocellular Carcinoma in Cirrhotic Patients: Current Knowledge and Future Directions. Hepatology Forum, 2020, , .	0.3	2
380	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arquivos De Gastroenterologia, 2020, 57, 1-20.	0.3	22
381	Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer. Aging, 2020, 12, 3371-3387.	1.4	83
382	Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma. Oncotarget, 2016, 7, 45637-45648.	0.8	22
383	Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy. Oncotarget, 2016, 7, 58553-58562.	0.8	3
384	Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study. Oncotarget, 2016, 7, 85603-85612.	0.8	3
385	The association of variants in <i>PNPLA3</i> and <i>GRP78</i> and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget, 2016, 7, 86791-86802.	0.8	16
386	Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget, 2017, 8, 46020-46033.	0.8	29
387	Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget, 2017, 8, 92431-92441.	0.8	41
388	Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. Oncotarget, 2017, 8, 106499-106510.	0.8	5
389	Autophagy-based survival prognosis in human colorectal carcinoma. Oncotarget, 2015, 6, 7084-7103.	0.8	50
390	A five-miRNA signature with prognostic and predictive value for <i>MGMT</i> promoter-methylated glioblastoma patients. Oncotarget, 2015, 6, 29285-29295.	0.8	49
391	Risk prediction models for hepatocellular carcinoma in different populations. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 150-160.	0.7	10
392	Risk stratification of HBV infection in Asia-Pacific region. Clinical and Molecular Hepatology, 2014, 20, 223.	4.5	19
393	Personalized treatment of hepatitis B. Clinical and Molecular Hepatology, 2015, 21, 1.	4.5	24

#	ARTICLE	IF	CITATIONS
394	The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 319-326.	4.5	73
395	Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 170-178.	4.5	49
396	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399.	4.5	20
397	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8867.	1.4	5
398	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , 2013, 19, 8887.	1.4	36
399	Occult hepatitis B virus and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 5951.	1.4	53
400	Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. <i>World Journal of Gastroenterology</i> , 2014, 20, 6244.	1.4	24
401	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 1398-1408.	1.4	14
402	Cost-effectiveness of Early Detection of Inactive and Treatment of Active Cases in a High Endemic Chronic Hepatitis B Region. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2013, 05, .	0.1	1
403	Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1742.	0.8	19
404	Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. <i>World Journal of Hepatology</i> , 2015, 7, 2133.	0.8	5
405	Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 175.	0.6	25
406	Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 962-968.	1.4	8
407	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. <i>Gut and Liver</i> , 2017, 11, 528-534.	1.4	22
408	A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model. <i>Hepatitis Monthly</i> , 2016, 16, e37435.	0.1	7
409	Hepatic Arterial Blood Flow Index Is Associated with the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B Virus Infection. <i>Hepatitis Monthly</i> , 2020, 20, .	0.1	1
410	Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3595-3604.	0.5	77
411	Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. <i>PeerJ</i> , 2020, 8, e8497.	0.9	9

#	ARTICLE	IF	CITATIONS
412	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	1.8	48
413	A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoteric Acid-Enhanced MRI Features. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1877-1886.	1.9	7
414	Cancer Prevention, Screening, and Early Detection. , 2014, , 322-359.e12.		1
415	Hepatitis Viruses: Hepatocellular Carcinoma. , 2014, , 785-804.		0
416	Epidemiology of Virus Infection and Human Cancer. , 2015, , 23-47.		1
417	Viral Factors Affecting Disease Progression. , 2018, , 119-133.		1
419	II. Reduction of hepatocellular carcinoma incidence in nucleos (t) ide analogues era. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 19-25.	0.0	0
420	Treatment of Hepatitis B. , 2018, , 485-500.e5.		0
421	Prevention of Hepatocarcinogenesis in Liver Cirrhosis. , 2019, , 159-166.		0
422	The Management of Hepatocellular Carcinoma. , 2020, , 237-271.		1
423	Rizikov's factory a surveillance hepatocelulárního karcinomu. <i>Vnitřní Lekarství</i> , 2019, 65, 583-587.	0.1	0
425	Prediction of HCC Using Liver Stiffness Measurements. , 2020, , 375-382.		0
426	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 1.	0.5	13
427	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	0.6	3
428	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. <i>Hepatology International</i> , 2021, 15, 1421-1430.	1.9	15
429	An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic. <i>Canadian Liver Journal</i> , 2020, 3, 309-321.	0.3	0
430	Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load. <i>American Journal of Cancer Research</i> , 2015, 5, 756-71.	1.4	9
432	Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B. <i>Cancers</i> , 2021, 13, 5609.	1.7	5



#	ARTICLE	IF	CITATIONS
433	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 3091.	1.8	13
434	The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 351-361.	4.5	17
435	Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin. <i>Cell Death and Disease</i> , 2021, 12, 1093.	2.7	9
436	How to interpret viral markers in the management of chronic hepatitis B infection. <i>Clinical Microbiology and Infection</i> , 2022, 28, 355-361.	2.8	1
437	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	1.7	6
438	Fatty Liver Disease: Diagnosis and Stratification. <i>Annual Review of Medicine</i> , 2022, 73, 529-544.	5.0	17
439	A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 115-123.	1.0	3
440	Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. <i>World Journal of Gastroenterology</i> , 2021, 27, 7497-7508.	1.4	11
441	Viral hepatitis in 2021: The challenges remaining and how we should tackle them. <i>World Journal of Gastroenterology</i> , 2022, 28, 76-95.	1.4	15
442	A Primary Screening Method for Liver Cancer in Chronic Hepatitis B Carriers: A Prospective Community-Based Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 762662.	1.3	1
443	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 500.	1.8	37
444	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. <i>Cancers</i> , 2022, 14, 621.	1.7	34
445	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. <i>Wellcome Open Research</i> , 0, 7, 32.	0.9	4
446	A hepatocellular carcinoma komplex kezelé. <i>Orvosi Hetilap</i> , 2022, 162, 2-31.	0.1	1
448	Models to Predict Development or Recurrence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. <i>Current Gastroenterology Reports</i> , 2022, 24, 1-9.	1.1	10
449	Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment. <i>World Journal of Gastroenterology</i> , 2022, 28, 665-674.	1.4	1
450	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	1.9	23
451	Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts. <i>Advances in Cancer Research</i> , 2022, , .	1.9	0

#	ARTICLE	IF	CITATIONS
452	Hepatocellular Carcinoma Risk Prediction in the NIH-AARP Diet and Health Study Cohort: A Machine Learning Approach. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 69-81.	1.8	0
453	Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 546-552.	0.8	3
454	PAGE-B and REACH-B Predicts the Risk of Developing Hepatocellular Carcinoma in Chronic Hepatitis B Patients from Northeast, Brazil. <i>Viruses</i> , 2022, 14, 732.	1.5	3
455	A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2022, 77, 632-641.	1.8	19
456	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 276-331.	4.5	43
457	Genetic associations in chronic hepatitis B infection: toward developing polygenic risk scores. <i>Future Microbiology</i> , 2022, 17, 541-549.	1.0	0
458	Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1919-1938.	0.8	15
459	Precision medicine in the era of potent antiviral therapy for chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1191-1196.	1.4	6
460	Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: A meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101930.	0.7	0
463	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alafenamide. <i>Hepatology Communications</i> , 2022, 6, 1881-1894.	2.0	7
464	Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies. <i>Npj Precision Oncology</i> , 2022, 6, 28.	2.3	17
465	Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 763-763.	1.9	0
466	Editorial: incorporating liver stiffness to risk scores for HCC in patients with chronic hepatitis B treated with oral antivirals: ready to use or not?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 753-754.	1.9	0
467	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. <i>Wellcome Open Research</i> , 0, 7, 32.	0.9	2
468	Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Viruses</i> , 2022, 14, 986.	1.5	37
469	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. <i>Wellcome Open Research</i> , 0, 7, 32.	0.9	8
470	Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high-risk chronic hepatitis B patients for HCC surveillance in Thailand. <i>JGH Open</i> , 0, , .	0.7	2
471	Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of $\alpha$ -Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
472	Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211027.	1.1	1
473	Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. <i>American Journal of Gastroenterology</i> , 2022, 117, 1444-1453.	0.2	4
474	Moving Away From a One-Size-Fits-All Approach to Hepatocellular Carcinoma Surveillance. <i>American Journal of Gastroenterology</i> , 2022, 117, 1409-1411.	0.2	2
475	Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1036-1048.	3.7	9
476	Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1503-1512.e4.	2.4	3
477	Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk. Reply.. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	0
478	What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. <i>JHEP Reports</i> , 2022, 4, 100578.	2.6	9
480	Risk stratification and early detection biomarkers for precision HCC screening. <i>Hepatology</i> , 2023, 78, 319-362.	3.6	13
481	Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 987-997.	1.8	3
482	Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. <i>Hepatology</i> , 2023, 77, 606-618.	3.6	19
483	Risk stratification of primary liver cancer. <i>World Journal of Clinical Cases</i> , 2022, 10, 9545-9549.	0.3	1
484	It's not all about the virus—On the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B. <i>Hepatology</i> , 2023, 77, 352-354.	3.6	2
485	Evaluation of the Hepatocellular Carcinoma Predictive Scores PAGE-B and mPAGE-B among Brazilian Patients with Chronic Hepatitis B Virus Infection. <i>Viruses</i> , 2022, 14, 1968.	1.5	2
486	Risk of HCC in Patients with HBV, Role of Antiviral Treatment. <i>Current Hepatology Reports</i> , 2022, 21, 76-86.	0.4	2
487	Identification of Warning Transition Points from Hepatitis B to Hepatocellular Carcinoma Based on Mutation Accumulation for the Early Diagnosis and Potential Drug Treatment of HBV-HCC. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-29.	1.9	0
488	A Lower HCC Incidence in Chronic HBV-Infected Patients Recovered from Acute-on-Chronic Liver Failure: A Prospective Cohort Study. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	1
489	Surveillance for Patients at Risk of Developing Hepatocellular Carcinoma. <i>Updates in Surgery Series</i> , 2023, , 183-190.	0.0	0
490	New indexes derived from routine blood tests and their clinical application in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 102043.	0.7	2

#	ARTICLE	IF	CITATIONS
491	Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
492	Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 6613.	1.0	0
493	Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries. <i>JHEP Reports</i> , 2023, 5, 100623.	2.6	5
494	The role of circadian gene timeless in gastrointestinal cancers. <i>Gene Reports</i> , 2023, 30, 101722.	0.4	0
495	Update on the role of elastography in liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211406.	1.4	12
496	Development and validation of a risk prediction model for incident liver cancer. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
497	Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis. <i>Diagnostics</i> , 2023, 13, 3.	1.3	5
499	Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma. <i>Biology</i> , 2023, 12, 188.	1.3	1
500	Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study. <i>American Journal of Gastroenterology</i> , 2023, Publish Ahead of Print, .	0.2	1
501	The imitator of immune-tolerant chronic hepatitis B: A killer in disguise. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 363-366.	4.5	1
502	Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the <scp>REVEALâ€œHBV</scp> and <scp>REVEALâ€œHCV</scp> cohort studies. <i>International Journal of Cancer</i> , 2023, 153, 44-53.	2.3	1
503	Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 605-622.	4.5	9
504	Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
505	Prediction Model with HLA-A*33:03 Reveals Number of Days to Develop Liver Cancer from Blood Test. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4761.	1.8	0
506	A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B. <i>Viruses</i> , 2023, 15, 724.	1.5	2
507	Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 869-890.	4.5	4
508	A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study. <i>PeerJ</i> , 0, 11, e15014.	0.9	1
509	Entecavir versus tenofovir disoproxil fumarate on the reduction of incidence of hepatocellular carcinoma in patients with chronic hepatitis Bâ€related liver cirrhosis. <i>Advances in Digestive Medicine</i> , 2024, 11, 16-23.	0.1	0

#	ARTICLE	IF	CITATIONS
510	ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. Journal of Hepatology, 2023, 79, 362-377.	1.8	34
511	Staging liver fibrosis with shear wave elastography. , 2024, , 95-124.		0
513	Acoustic radiation force impulse predicts long-term outcomes in a large-scale cohort: High liver cancer, low comorbidity in hepatitis B virus. World Journal of Gastroenterology, 0, 29, 2188-2201.	1.4	0
514	Research Progress on the Need for Antiviral Therapy in Chronic HBV Infected Patients with Normal ALT. Advances in Clinical Medicine, 2023, 13, 5360-5365.	0.0	0
520	Hepatocellular carcinoma surveillance “utilization, barriers and the impact of changing aetiology. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 797-809.	8.2	12
525	Hepatitis Viruses: Hepatocellular Carcinoma. , 2023, , 1-36.		0